Instil Bio (TIL) Competitors $34.23 -3.28 (-8.74%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$34.20 -0.02 (-0.07%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TIL vs. PRAX, ARDX, LENZ, OCS, ZYME, NTLA, NUVB, PHAR, IMNM, and AVBPShould you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Praxis Precision Medicines (PRAX), Ardelyx (ARDX), LENZ Therapeutics (LENZ), Oculis (OCS), Zymeworks (ZYME), Intellia Therapeutics (NTLA), Nuvation Bio (NUVB), Pharming Group (PHAR), Immunome (IMNM), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. Instil Bio vs. Its Competitors Praxis Precision Medicines Ardelyx LENZ Therapeutics Oculis Zymeworks Intellia Therapeutics Nuvation Bio Pharming Group Immunome ArriVent BioPharma Instil Bio (NASDAQ:TIL) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Do insiders and institutionals have more ownership in TIL or PRAX? 60.6% of Instil Bio shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 47.2% of Instil Bio shares are held by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher earnings and valuation, TIL or PRAX? Praxis Precision Medicines has higher revenue and earnings than Instil Bio. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInstil BioN/AN/A-$156.09M-$11.97-2.86Praxis Precision Medicines$8.12M111.10-$123.28M-$10.72-4.13 Do analysts rate TIL or PRAX? Instil Bio currently has a consensus target price of $119.00, indicating a potential upside of 247.65%. Praxis Precision Medicines has a consensus target price of $109.90, indicating a potential upside of 148.08%. Given Instil Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Instil Bio is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is TIL or PRAX more profitable? Instil Bio has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -9,409.22%. Instil Bio's return on equity of -37.44% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Instil BioN/A -37.44% -25.08% Praxis Precision Medicines -9,409.22%-54.86%-50.52% Does the media favor TIL or PRAX? In the previous week, Praxis Precision Medicines had 3 more articles in the media than Instil Bio. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 3 mentions for Instil Bio. Praxis Precision Medicines' average media sentiment score of 0.30 beat Instil Bio's score of 0.30 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Instil Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor TIL or PRAX? Instil Bio received 49 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. However, 75.34% of users gave Praxis Precision Medicines an outperform vote while only 50.49% of users gave Instil Bio an outperform vote. CompanyUnderperformOutperformInstil BioOutperform Votes10450.49% Underperform Votes10249.51% Praxis Precision MedicinesOutperform Votes5575.34% Underperform Votes1824.66% Which has more risk & volatility, TIL or PRAX? Instil Bio has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500. SummaryInstil Bio and Praxis Precision Medicines tied by winning 9 of the 18 factors compared between the two stocks. Get Instil Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TIL vs. The Competition Export to ExcelMetricInstil BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$224.52M$3.09B$5.57B$8.50BDividend YieldN/A1.56%5.28%4.16%P/E Ratio-2.9632.6326.6319.64Price / SalesN/A455.18407.99152.17Price / CashN/A168.6838.2534.64Price / Book0.993.366.964.60Net Income-$156.09M-$72.35M$3.23B$248.06M7 Day Performance4.07%0.30%-1.13%-0.94%1 Month Performance157.56%16.40%8.59%3.52%1 Year Performance227.87%-15.52%33.63%14.02% Instil Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TILInstil Bio2.996 of 5 stars$34.23-8.7%$119.00+247.6%+226.0%$224.52MN/A-2.96410Short Interest ↑Gap UpPRAXPraxis Precision Medicines2.7396 of 5 stars$44.51-0.1%$109.90+146.9%+10.6%$906.62M$8.12M-4.32110Analyst ForecastGap DownARDXArdelyx3.9268 of 5 stars$3.76+2.2%$10.39+176.3%-44.5%$899.60M$361.71M-23.5090Positive NewsInsider TradeAnalyst RevisionLENZLENZ Therapeutics1.6484 of 5 stars$31.22-2.3%$46.60+49.3%+55.7%$899.55MN/A-17.64110High Trading VolumeOCSOculis1.7527 of 5 stars$19.92flat$31.50+58.1%+60.1%$869.75M$980K-10.322Positive NewsShort Interest ↑ZYMEZymeworks1.8536 of 5 stars$12.45-1.2%$21.00+68.7%+39.1%$866.23M$93.38M-8.30460Positive NewsGap DownNTLAIntellia Therapeutics4.5921 of 5 stars$8.28+2.3%$34.95+322.1%-68.0%$857.67M$45.57M-1.52600Analyst RevisionGap DownHigh Trading VolumeNUVBNuvation Bio2.9534 of 5 stars$2.51+1.2%$7.83+212.1%-42.3%$854.06M$10.96M-1.1660News CoverageAnalyst ForecastHigh Trading VolumePHARPharming Group2.1795 of 5 stars$11.81-0.4%$30.00+154.0%+26.4%$806.69M$320.71M-45.42280News CoverageShort Interest ↑IMNMImmunome1.6337 of 5 stars$9.27+1.5%$23.33+151.7%-42.6%$806.60M$10.94M-1.1440News CoveragePositive NewsGap DownAVBPArriVent BioPharma1.4705 of 5 stars$23.60+0.3%$39.29+66.5%+23.6%$804.69MN/A-6.2640Positive News Related Companies and Tools Related Companies PRAX Competitors ARDX Competitors LENZ Competitors OCS Competitors ZYME Competitors NTLA Competitors NUVB Competitors PHAR Competitors IMNM Competitors AVBP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TIL) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Instil Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
